ArriVent BioPharma’s latest quarterly report confirms continued clinical advancement of its lead candidate, firmonertinib, alongside other pipeline assets. The company remains pre-revenue, supported by exclusive licensing agreements with key partners Allist and Lepu Biopharma, and depends heavily on third-party manufacturing predominantly based in China. With solid liquidity as of March 2026, ArriVent faces typical biopharma risks including trial delays, regulatory uncertainty, and capital requirements that could constrain long-term growth absent successful clinical outcomes or additional funding.